Ribozyme and omics

Anti-cancer development based on RNA Platform technology Core competence to meet diverse unmet medical needs

RZ-002

Glioblastoma

Medical unmet needs
  • High mortality rate

    The most common 1˚ brain tumor (glial cell)

    Malignancy in Central Nervous System

    Average survival rate : 12-15 months, Survival rate for 5 years: less than 3-5%

    Mortality : within a year (50% of patients), within 3 years (90% of patients)

  • Lack of effective therapies

    Standard treatment : aggressive resection followed by radiation with temozolomide (TMZ)

    Median survival rate : Around 15-17 months

    Not complete resection due to Invasive growth, multiple lesions, etc., resistance, side effects, and recurrence

  • In need of new therapies

    Ad-TK alone: safety but low efficacy in Phase III

    Telomerase overexpressed in 85-90% (80% mutant Tert promoter), but tel length heterogeneity including GSCs; poor prognosis
    → Tel inhibitor largely failed in Clinics

    Immune evasion Immune checkpoint inhibitor (side effects, combination treatment)